Search

Andrea Panaggio

from Newport, RI
Age ~71
Get Report
Also known as:
Andrea Cavallaro, Andre A Cavallaro
Related to:
Kathy M Lewis, 70Lauren PanaggioKathleen B Bradley, 65Mark C Cavallaro, 68
Connected to:
Kevin R Panaggio, 57Thomas A Panaggio, 67John A Panagides, 80Dimitrios Panagiotopoulos, 60Dionysios Panagiotopoulos, 34Evangelia Panagiotou, 88Giannis K Panagiotopoulos, 40Jane L Panagiotakos, 62Joanna Panagiotopoulos, 37Kostas Panagiotou, 53

Andrea Panaggio Phones & Addresses

  • Newport, RI
  • Somerset, NJ
  • 5 Tindall Trl, Princeton Junction, NJ 08550 (609) 275-0056
  • Jamesburg, NJ
  • Cranbury, NJ
  • 5 Tindall Trl, Princeton Jct, NJ 08550 (609) 672-3268

Work

Position: Administrative Support Occupations, Including Clerical Occupations

Professional Records

License Records

Andrea Panaggio

Address:
West Windsor, NJ
License #:
28RI01791800 - Active
Category:
Pharmacy
Issued Date:
Jan 8, 1984
Expiration Date:
Apr 30, 2019
Type:
Pharmacist

Andrea Panaggio

License #:
RPH02307 - Active
Category:
Pharmacy
Issued Date:
Dec 8, 1976
Expiration Date:
Jun 30, 2017
Type:
Pharmacist

Andrea Panaggio

Address:
West Windsor, NJ
License #:
28RI01791800 - Active
Category:
Pharmacy
Issued Date:
Jan 8, 1984
Expiration Date:
Apr 30, 2019
Type:
Pharmacist

Publications

Us Patents

Pharmaceutical Compositions, Dosage Forms And Methods For Oral Administration Of Epothilones

View page
US Patent:
6576651, Jun 10, 2003
Filed:
Jan 25, 2002
Appl. No.:
10/057390
Inventors:
Rebanta Bandyopadhyay - Portage MI
Timothy M. Malloy - Yardley PA
Andrea Panaggio - West Windsor NJ
Krishnaswamy Srinivas Raghavan - Cranbury NJ
Sailesh Amilal Varia - Princeton Junction NJ
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31425
US Classification:
514365, 514183, 514450
Abstract:
The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.

Methods Of Administering Epothilone Analogs For The Treatment Of Cancer

View page
US Patent:
6670384, Dec 30, 2003
Filed:
Jan 23, 2002
Appl. No.:
10/055653
Inventors:
Rebanta Bandyopadhyay - Portage MI
Timothy M. Malloy - Yardley PA
Andrea Panaggio - West Windsor NJ
Krishnaswamy Srinivas Raghavan - Cranbury NJ
Sailesh Amilal Varia - Princeton Junction NJ
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31365
US Classification:
514365, 514183
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0. 1 mg/mL to about 0. 9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringers Injection.

Parenteral Formulation For Epothilone Analogs

View page
US Patent:
7022330, Apr 4, 2006
Filed:
Jan 17, 2002
Appl. No.:
10/051727
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 9/00
US Classification:
424400, 424422, 514365, 514 37, 514183, 548146
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0. 1 mg/mL to about 0. 9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.

Pharmaceutical Compositions, Dosage Forms And Methods For Oral Administration Of Epothilones

View page
US Patent:
RE40387, Jun 17, 2008
Filed:
Jun 9, 2005
Appl. No.:
11/149501
Inventors:
Rebanta Bandyopadhyay - Hyderabad, IN
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Marvin Barry Cohen - Newtown PA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/425
A61K 31/33
A61K 31/497
A61K 31/335
US Classification:
514365, 514183, 51425407, 514450
Abstract:
The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.

Parenteral Formulation For Epothilone Analogs

View page
US Patent:
8632788, Jan 21, 2014
Filed:
Nov 4, 2008
Appl. No.:
12/264375
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
Timothy M. Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Sailesh Amilal Varia - Princeton Junction NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 9/00
A61K 31/425
US Classification:
424400, 514365
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0. 1 mg/mL to about 0. 9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.

Parenteral Formulation For Epothilone Analogs

View page
US Patent:
20060013836, Jan 19, 2006
Filed:
Sep 14, 2005
Appl. No.:
11/226017
Inventors:
Rebanta Bandyopadhyay - Portage MI, US
Timothy Malloy - Yardley PA, US
Andrea Panaggio - West Windsor NJ, US
Krishnaswamy Raghavan - Cranbury NJ, US
Sailesh Varia - Princeton Junction NJ, US
International Classification:
A61K 31/427
A61K 9/00
US Classification:
424400000, 514365000
Abstract:
A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.

Steroid Ointment Formulation

View page
US Patent:
48681687, Sep 19, 1989
Filed:
Nov 13, 1987
Appl. No.:
7/120276
Inventors:
Richard L. O'Laughlin - North Brunswick NJ
Andrea Panaggio - Jamesburg NJ
Sailesh A. Varia - Plainsboro NJ
Assignee:
E. R. Squibb & Sons, Inc. - Princeton NJ
International Classification:
A61K 3156
US Classification:
514179
Abstract:
A steroid ointment formulation which has enhanced physical and chemical stability is formed of 11. beta. ,17. alpha. )-17-(ethylthio)-9. alpha. -fluoro-11. beta. -hydroxy-17-(me thylthio)androsta-1,4-dien-3-one (tipredane), and a vehicle containing as major ingredients propylene glycol and water, cetearyl alcohol and ceteareth 20 or other dispersing agent for propylene glycol, together with a sodium or potassium citrate and magnesium hydroxide buffer to impart a neutral or slightly alkaline apparent pH (5 to 9), a non-acidic long chain fatty acid wax to impart proper consistency to the ointment and sodium metabisulfite and butylated hydroxy toluene as antioxidants, together with thickeners, emollients, lubricants and other conventional ointment formulation ingredients.

Steroid Cream Formulation

View page
US Patent:
48681695, Sep 19, 1989
Filed:
Nov 13, 1987
Appl. No.:
7/120278
Inventors:
Richard L. O'Laughlin - North Brunswick NJ
Andrea Panaggio - Jamesburg NJ
Sailesh A. Varia - Plainsboro NJ
Assignee:
E. R. Squibb & Sons, Inc. - Princeton NJ
International Classification:
A61K 3156
US Classification:
514179
Abstract:
A steroid cream formulation which has enhanced physical and chemical stability is formed of (11. beta. ,17. alpha. )-17-(ethylthio)-9. alpha. -fluoro-11. beta. -hydroxy-17-(m ethylthio)androsta-1,4-dien-3-one (tipredane), and a vehicle containing as major ingredients glyceryl monostearate having an acid value of greater than 4, propylene glycol and water together with a sodium citrate or potassium citrate buffer, a non-acidic long chain fatty acid wax to impart proper consistency, and sodium metabisulfite as an antioxidant, together with emulsifiers, skin conditioners, emollients, lubricants and other conventional cream formulation ingredients.
Control profile
Andrea Panaggio from Newport, RI, age ~71 Get Report